Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction-Reference-Cited by-同舟云学术

Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction

Published:2013-11-27 Issue: Volume: Page:
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Ragonese Marta,Alibrandi Angela,Di Bella Gianluca,Salamone Ignazio,Puglisi Soraya,Cotta Oana Ruxandra,Torre Maria Luisa,Ferrau Francesco,Ruggeri Rosaria Maddalena,Trimarchi Francesco,Cannavo Salvatore

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s12020-013-0115-8.pdf

Reference31 articles.

1. S. Melmed, Acromegaly. N. Engl. J. Med. 322, 966–977 (1990)

2. C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K. Jöckel, S. Möhlenkamp, R. Erbel, B. Saller, K. Mann, Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95, 3648–3656 (2010)

3. I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)

4. S. Cannavo, B. Almoto, G. Cavalli, S. Squadrito, G. Romanello, M.T. Vigo, F. Fiumara, S. Benvenga, F. Trimarchi, Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J. Clin. Endocrinol. Metab. 91, 3766–3772 (2006)

5. P. Schoenhagen, A.E. Stillman, S.S. Halliburton, R.D. White, CT of the heart: principles, advances, clinical uses. Clevel. Clin. J. Med. 72, 88–89 (2005)

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly;Hormones;2023-11-20

2. Assessment of Osteoprotegerin and RANKL Levels and Several Cardiovascular Risk Scoring Systems in Acromegaly;2023-07-18

3. How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients;Endocrine;2023-03-31

4. Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients;Experimental and Clinical Endocrinology & Diabetes;2021-12-23

5. Advances in Research on the Cardiovascular Complications of Acromegaly;Frontiers in Oncology;2021-04-02